Zevra Therapeutics, Inc.
NASDAQZVRA short interest surges 25.7% in one week to 11.0% of float, driven by stock rallying 23% amid analyst upgrade wave.
Snapshot as of 22 Jun 2026
Zevra Therapeutics is caught in an unusual tug-of-war this week: a stock up 26% over five days is simultaneously attracting a coordinated wave of analyst upgrades and a sharp build in short interest — two signals that…
Zevra Therapeutics heads into the post-earnings stretch with a clean beat under its belt and shorts sitting at a meaningful but steady 8.5% of the float. Q1 2026 results, reported after the close on May 6, came in well…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ZVRA — free to start on ORTEX.
Sign up for free →Open ZVRA on ORTEX